Antibody based therapeutic development for coronaviruses

The first human coronavirus was isolated from individuals suffering from the common cold in the 1960’s. Since then, three highly pathogenic human coronaviruses have arisen in the last two decades; SARS in 2002, MERS in 2012 and the devastating COVID-19 pandemic. It is critical we understand how current and emerging coronaviruses infect humans and more importantly, develop therapeutic agents to tackle current disease, resist future SARS-CoV-2 variants and new coronavirus-origin pandemics.